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Abstract: Obesity is a multifactorial disease characterized by the excessive accumulation 
of fat in adipose tissue and peripheral organs. Its derived metabolic complications are 
mediated by the associated oxidative stress, inflammation and hypoxia. Oxidative stress is 
due to the excessive production of reactive oxygen species or diminished antioxidant 
defenses. Genetic variants, such as single nucleotide polymorphisms in antioxidant defense 
system genes, could alter the efficacy of these enzymes and, ultimately, the risk of obesity; 
thus, studies investigating the role of genetic variations in genes related to oxidative stress 
could be useful for better understanding the etiology of obesity and its metabolic 
complications. The lack of existing literature reviews in this field encouraged us to gather 
the findings from studies focusing on the impact of single nucleotide polymorphisms in 
antioxidant enzymes, oxidative stress-producing systems and transcription factor genes 
concerning their association with obesity risk and its phenotypes. In the future, the 
characterization of these single nucleotide polymorphisms (SNPs) in obese patients could 
contribute to the development of controlled antioxidant therapies potentially beneficial for 
the treatment of obesity-derived metabolic complications. 









Obesity is increasing dramatically and has already become a major clinical challenge for healthcare 
systems worldwide [1]. Obesity is a multifactorial disease, influenced by both genetic and 
environmental factors. The onset of obesity is due mainly to low energy expenditure (e.g., from 
exercise) combined with high caloric intake. This leads to an excessive accumulation of fat in the 
adipose tissue, accompanied by low-grade inflammation, hypoxia and oxidative stress. 
Oxidative stress is defined as an imbalance between the reactive oxygen species (ROS) scavenging 
and producing systems in the organism. ROS include molecules, such as hydrogen peroxide (H2O2), 
superoxide (O2
•−) and the hydroxyl radical (OH−). The controlled production of these molecules is 
known to help protect against microorganisms during infectious processes, as well as contribute to 
normal functions in the cell, including proliferation, differentiation and signaling [2]. However, a  
non-physiological increase in ROS levels from excessive caloric intake, inflammation or hypoxia, or a 
decrease in the antioxidant capacity of the organism can lead to the aforementioned alterations. 
The antioxidant defense system maintains ROS homeostasis in the cells. It comprises both 
endogenous and exogenous antioxidants. Endogenous antioxidants include enzymes that degrade ROS 
at different levels and in different compartments inside and outside of the cells, such as glutathione 
peroxidases (GPXs), catalase (CAT), paraoxonases (PONs), superoxide dismutases (SODs), 
peroxiredoxins (PRDXs), glutathione reductase, thioredoxin reductase, heme-oxygenase 1, cytochrome 
c oxidase, as well as methionine sulphoxide reductase involved in the repair of oxidized proteins, 
xanthine oxidase, a drug metabolizing enzyme, and the cytochrome c oxidase complex, which regulates 
the electron transport chain. In addition, some of these enzymes require endogenous cofactors, such as 
glutathione and lipoic acid, in order to perform their ROS scavenging activities. Exogenous 
antioxidants include vitamins, carotenoids, polyphenols and trace elements, such as selenium and zinc, 
reviewed in [3]. 
It is known that genetic variations, such as single nucleotide polymorphisms (SNPs), can affect the 
functioning of antioxidant enzymes and increase the risk of certain diseases, such as cancer [3]. 
However, to our knowledge, the impact of genetic variations in the genes associated with oxidative 
stress regulation has not been fully studied nor reviewed in the context of obesity. Detailed studies in 
this field could clarify the mechanisms involved in the development of the comorbidities of obesity, 
such as metabolic syndrome and insulin resistance, even in the development of obesity itself [4]. Thus, 
the aim of this review is to summarize the current knowledge about the association of genetic 
variations in antioxidant defense system genes, oxidative stress producing systems and related 
transcription factors with obesity risk and phenotypes. 
In the future, the characterization of these SNPs in obese patients could contribute to the 
development of controlled antioxidant therapies that would be potentially beneficial for the prevention 
and treatment of obesity and its derived metabolic complications. 
2. Methodology 
We conducted a systematic review of the literature by using the PubMed database. The following 
phrases were included in the process: (1) “obesity” AND “polymorphism” AND “oxidative stress”, 
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limited to human studies, gave 47 results; (2) “obesity” AND “polymorphism” AND “oxidative 
stress”, limited to animal studies, gave eight results; (3) “obesity” AND “gene expression” AND 
“adipose tissue” AND “oxidative stress”, limited to human studies, gave 28 results; (4) “obesity” AND 
“gene expression” AND “adipose tissue” AND “oxidative stress”, limited to animal studies, gave 71 
results; (5) “obesity” AND “mechanisms” AND “gene” AND “oxidative stress”, limited to human 
studies, gave 31 results; and (6) “obesity” AND “mechanisms” AND “gene” AND “oxidative stress”, 
limited to animal studies, gave 30 results. A total of 215 results in English were obtained, and titles and 
abstracts were revised to select a total of 73 articles that were read in full. We included articles that had 
the clear aim of investigating the role of SNPs or genes on the risk of obesity or its metabolic 
complications. In addition, previous reviews focusing on conditions other than obesity were carefully 
examined in order to better characterize the role of antioxidants in the context of disease. Additional 
articles not found in this search were identified by exploring references in key articles, as well as by 
individual searches of specific genes. 
3. Oxidative Stress in Obesity 
The adipose tissue is an endocrine organ that produces a variety of molecules, including adipokines, 
such as adiponectin and leptin, and cytokines, such as tumor necrosis factor alpha (TNFα) and 
interleukins 1β (IL-1β) and 6 (IL-6) [5,6]. It is well known that adipose tissue in obese individuals 
undergoes many pathological changes, due to the accumulation of fat, such as inflammation, hypoxia 
and increased oxidative stress [7,8]. Upon the accumulation of excessive fat, the adipokine secretion 
profile becomes altered and peripheral tissues are affected, contributing to the appearance of health 
problems, such as dyslipidemia, hypertension, insulin resistance, diabetes and atherosclerosis (Figure 1). 
Figure 1. A schematic diagram of the multifactorial character of obesity. These factors 
influence the development of obesity and its associated comorbidities by altering adipokine 
secretion, hypoxia and inflammation with associated oxidative stress. The presence of 
certain single nucleotide polymorphisms (SNPs) reviewed here can increase the risk of 
obesity and its comorbidities, further worsening the metabolic profile. 
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The higher fat and carbohydrate intakes associated with obesity may be responsible in part for the 
enhanced ROS production, due to the saturation of the electron transport chain. Free fatty acids (FFAs) 
have had this effect in mouse models [9], and in humans, FFAs generate high H2O2 levels in the 
mitochondria [10]. Thus, the link between obesity and enhanced oxidative stress might be due to the 
hyperglycemia, high circulating FFA, decreased antioxidant defenses and chronic inflammation 
associated with obesity. Indeed, in obese humans, indicators of cellular and systemic oxidative stress 
have been found in many studies (Table 1). Levels of plasma thiobarbituric acid reactive substances 
(TBARS) and urinary 8-epi-prostaglandin F2α (8-epi-PGF2α) were augmented in obese  
individuals [11,12]. A study conducted in severely obese children found similar results, with higher  
8-isoprostane F2α and malondialdehyde (MDA) plasma concentrations, as well as increased nitric 
oxide production, as reflected by higher nitrite, nitrate and nitrotyrosine values, in obese children [13]. 
The activities of antioxidant enzymes, such as glutathione peroxidase and catalase have also been 
observed to be lowered in obesity, as will be described below [14,15]. 
Table 1. Common markers of oxidative stress found in obesity in humans. 
 Marker References 
Adults ↑ F2α-isoprostane [12,16–18] 
 ↑ MDA/TBARS [11,19,20] 
 ↑ Ox-LDL [16,21,22] 
 ↓ PON1 activity [11,23,24] (Non-significant: [25–27]) 
 ↓ TAC [27] 
Children ↑ AOPPs [28] 
 ↓ CAT activity [15] 
 ↑ F2α-isoprostane [13,29–31] 
 ↓ GPX activity [14] (pubertal) (Non-significant: [15], prepubertal) 
 ↑ MDA [13,32] 
 ↑ Nitrite/nitrate [14] 
 ↑ NO [13] 
 ↑ Ox-LDL [33] 
 ↓ PON1 activity [34–36] (Non-significant: [37]) 
 ↓ TAC [38] 
AOPPs, advanced oxidation protein products; CAT, catalase; GPX, glutathione peroxidases;  
MDA, malondialdehyde; NO, nitric oxide; Ox-LDL, oxidized low-density lipoproteins (LDL);  
PON1, paraoxonase 1; TAC, total antioxidant capacity; TBARS, thiobarbituric acid reactive substances. 
In addition to ROS produced by caloric intake, cells also have ROS-producing systems for 
physiological processes, including protein folding in the endoplasmic reticulum, xenobiotic 
metabolism, DNA metabolism and the nicotinamide adenine dinucleotide phosphate-oxidase (NADPH 
oxidase) complex that produces ROS in response to insulin and cytokines (like TNFα) as part of a 
signal-transducing system [39]. The alteration of these systems can generate additional quantities of 
ROS and contribute to higher oxidative stress levels. 
The enhanced oxidative stress associated with obesity leads to the oxidation of proteins, lipids and 
DNA and, eventually, to alterations in the modulation of gene expression and signaling pathways [40]. 
Indeed, these alterations in cellular and tissue components contribute to chronic inflammation and, 
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thus, to the development of diseases, such as obesity and insulin resistance [41,42]. In fact, chronic 
oxidative stress is known to induce inflammation, and obesity is considered a disease of chronic  
low-grade inflammation [43]. In addition, ROS are a key element in the adipogenic process, and the 
possibility exists that their excessive increase helps in the development of obesity by a stimulation of 
adipogenesis [4,44]. 
The role of transcription factors in the development of obesity comorbidities is gaining attention. 
Peroxisome proliferator activated receptor gamma (PPARγ) and PPARγ coactivator-1α (PGC1α) are 
very well-known transcription factors in the adipose tissue. Some studies have suggested that PPARγ 
is implicated in cellular responses against oxidative stress [41,45,46], whereas the role of PGC1α in the 
induction of the expression of ROS detoxifying enzymes has been better characterized [47,48]. In the 
present review, we will focus on the known variations in these genes and go through the findings 
concerning their impact on the risk of obesity insulin resistance. Nuclear erythroid factor 2-like 2 
(NRF2), one of the most important transcription factors in the oxidative stress response, will also be 
considered with respect to its role in ROS responses and obesity.  
4. Enzymatic Antioxidant Defense Genes  
4.1. Glutathione Peroxidases 
The GPX family is composed of at least eight isoenzymes in mammals and constitutes one of the 
main antioxidant defense systems, using glutathione to degrade H2O2 [49]. GPX1 is the most abundant 
isoenzyme, ubiquitous in the intracellular fraction and formed by four 22-kDa subunits, each carrying 
one selenocysteine. GPX2 is the gastrointestinal form, and GPX3 circulates in blood and is secreted 
from the kidney [50]. GPX5 and 6 are specific from the epididymis and the olfactory epithelium, 
respectively. Finally, GPX 4, 7 and 8 are the earliest in evolution, as they share sequences with 
protozoa and invertebrates [51]. GPX4 is a membrane-bound form, important for spermatogenesis. 
Interestingly, GPX7 (also non-selenocysteine-containing phospholipid hydroperoxide glutathione 
peroxidases or NPGPX) and GPX8 have no clear enzymatic activity. However, the endoplasmic 
reticulum enzyme, GPX7, expressed in adipocytes and their precursors, was shown to act as an 
oxidative stress sensor/transducer in the regulation of ROS accumulation [52]. 
In animal studies, cellular and extracellular GPX activity was shown to be lower in the adipose 
tissue of obese rats [53]. In a study carried out with obese mice, the mRNA expression of GPX1 was 
increased after caloric restriction [54]. However, GPX1 knockout mice are protected against high-fat 
diet-induced insulin resistance and atherosclerosis [55–57]. Concerning GPX3, in a study involving 
obese mice, GPX3 expression was found to be selectively decreased in adipose tissue and plasma; the 
same effect was achieved by treating mice with either both TNFα or hypoxia. The use of antioxidants 
and the anti-diabetic drug, rosiglitazone, both succeeded in restoring GPX3 expression in adipose 
tissue, improving the insulin resistance phenotype and attenuating the inflammatory gene expression  
pattern [58]. Another study that supports GPX3 activity against obesity showed that estrogen receptor 
α activates GPX3 transcription and that this mediates its fat mass reducing effects [59]. In the case of 
GPX7, an elegant study showed that the loss of GPX7 enhances oxidative stress [52] and adipocyte 
hypertrophy and increases white adipose tissue mass by stimulating adipogenesis [4] in mice. Finally, 
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in human studies, pubertal obese children with insulin resistance showed lower erythrocyte GPX activity 
than the control group [14], whereas no changes were observed in prepubertal obese children [15]. 
Regarding genetic variations, SNPs associated with obesity and insulin resistance have been 
described for the GPX1 and GPX7 genes (Figure 2, Table 2). The GPX1 gene harbors a well-known 
missense polymorphism (C to T substitution) at nucleotide 594 that results in the substitution of 
leucine for proline at codon 198 of the protein (Pro198Leu; rs1050450). Many studies have shown the 
Leu allele to be associated with worse outcomes for oxidative stress, central obesity and insulin 
resistance, with some sex-related differences. Male Leu allele (T) carriers had higher metabolic 
syndrome prevalence, demonstrating higher waist-hip ratios, triglycerides (TAG), insulin, homeostasis 
model assessment of β-cell function (HOMA-β) and systolic and diastolic blood pressures [60]. 
Women carrying the same allele showed higher body fat mass, insulin and homeostasis model 
assessment of insulin resistance (HOMA-IR). In an intervention study, the authors showed that 
nutritional supplementation with selenium from Brazil nuts was associated with higher DNA damage 
in Leu carriers [61]. Carriers of the Leu allele have also been shown to have significantly higher levels 
of lipoperoxides and MDA in low-density lipoproteins (LDL) [62]. It was shown that the combination 
of Pro198Leu SNP with the copy number variant (CNV) Ala5/Ala6 at codon7-11 decreases the 
activity of the enzyme by 40% in vitro [63]. In the same study, it was demonstrated that the 
combination of two other SNPs (-602A/G, 2C/T) decreased the transcriptional activity of GPX1 by 
25%. These data suggest that the Leu allele is associated with lower GPX activity and a subsequent 
higher oxidative stress from ROS, thus generating worse outcomes in obesity-associated phenotypes. 
In the case of GPX7, SNPs near this gene have been associated with lower GPX7 expression and 
increased adiposity in several populations. The variant, rs835337 (G/A), located upstream of the gene, 
was associated with body mass index (BMI) in adults. The minor allele (A) of this genetic variant was 
associated with decreased BMI and increased GPX7 expression in abdominal adipose tissue together 
with decreased serum MDA concentrations. In this way, the SNP confers protection against obesity 
potentially by a decrease in ROS levels. The proposed mechanism is that adipogenesis is impaired by 
the presence of lower ROS levels, needed for the normal adipogenic process [4]. In summary, GPXs 
with enzymatic activity seem to be involved in the protection against obesity-derived metabolic 
complications, whereas the sensor/transducer GPX7 regulates responses against ROS in the earlier 
steps of obesity development. 
4.2. Catalase 
CAT is one of the most important antioxidant enzymes in the cell, located in the peroxisomes.  
It degrades any H2O2 that exceeds the physiological levels. CAT expression was increased after caloric 
restriction in the adipose tissue of obese mice [54]; however, its expression in mice hearts has also 
been observed to be increased after 30 weeks of high-fat feeding, possibly to compensate for the 
observed significant decrease in CAT-specific activity [64]. Moreover, CAT erythrocyte activity was 
lower in children with insulin resistance and obesity [15,65]. 
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Figure 2. Effects of the main known SNPs of the antioxidant defense system genes in the 
cell on obesity. Dark orange and green boxes indicate higher or lower obesity risk 
associated with the SNP, respectively. Light orange boxes indicate conflicting results. Red 
and green arrows matching the color of an allele of the SNP indicate higher or lower 
enzyme activity associated with that allele. Dashed green arrows indicate activation. CAT, 
catalase; CuZn-SOD, copper-zinc superoxide dismutase; ETC, electron transport chain; 
GPX, glutathione peroxidase; GSH, reduced glutathione; GSSG, oxidized glutathione; 
HDL, high-density lipoprotein; HFD, high-fat diet; Mn-SOD, manganese superoxide 
dismutase; MsrA, methionine sulphoxide reductase A; NADPH, nicotinamide adenine 
dinucleotide phosphate; NPGPX, non-selenocysteine-containing phospholipid hydroperoxide 
glutathione peroxidases; NRF2, nuclear erythroid factor 2-like 2; O2
•−, superoxide; PGC1α, 
peroxisome proliferator-activated receptor γ coactivator-1α; PON1, paraoxonase 1; 
PPARγ, peroxisome proliferator activated receptor gamma; PRDX3, peroxiredoxin 3; 
TNFα, tumor necrosis factor alpha.  
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GPX1 rs1050450 594C/T,  
Pro198Leu 
C/T Leu male carriers have higher waist-hip ratio, TAG, insulin, HOMA-β, SBP, DBP 
Leu female carriers have higher body fat mass, insulin and HOMA-IR 
[60] 
    Leu carriers show higher DNA damage after Se supplementation [61] 
    Leu carriers have higher lipoperoxides and MDA in LDL [62] 
GPX1  Ala5/Ala6 + 
Pro198Leu 
 40% decrease in GPX1 activity [63] 
GPX1  -602A/G + 2C/T  25% decrease in transcriptional activity [63] 
GPX7 rs835337  G/A A allele Associated with decreased BMI in adults (British, Finnish and Han Chinese) and 
with increased GPX7 expression in abdominal adipose tissue and decreased serum MDA 
concentrations 
[4] 
CAT rs769214 -844A/G A/G Associated with prepubertal obesity, higher weight, BMI Z-score, A-FABP [15] 
CAT rs7943316 -89T/A A/T Associated with prepubertal obesity [15] 
CAT rs1049982 -20C/T C/T Associated with prepubertal obesity [15] 
CAT  -844G/-89A/-20T  Lower CAT expression under high oxidative stress conditions [66] 
PON1 rs662 Q192R G/A 192RR (Arg-Arg) individuals show higher activity degrading paraoxon [67] 
    R allele associated with higher obesity risk [26] 
    No association with obesity in Mexican adults [25] 
    No association with obesity in adolescents [68] 
    No association with obesity in prepubertal children [37] 
PON1 rs854560 L55M A/T 55LL (Leu-Leu) individuals have increased serum PON1 concentrations [35] 
PON1 rs854566  G/A Protection against prepubertal childhood obesity and lactonase activity [37] 
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PRDX3 rs3740562*  A/G Associated with higher BMI in Japanese adults when combined with high-fat diet [69] 
PRDX3 rs2271362*  C/T Associated with higher BMI in Japanese adults when combined with high-fat diet [69] 
PRDX3 rs7768*  G/C Associated with higher BMI in Japanese adults when combined with high-fat diet [69] 
PRDX3 rs3377*  A/C Associated with higher BMI in Japanese adults when combined with high-fat diet [69] 
MSRA rs7826222 rs545854 G/C Associated with WC in Europeans [70,71] 
    Associated with BMI in Hispanic women [72] 
    Associated with higher type 2 diabetes risk [73] 
    Not associated with BMI in Chinese [74] 
    Not associated with metabolic syndrome or visceral fat in Japanese [75,76] 
 rs473034  G/A Associated with extreme childhood obesity [77] 
 rs516175  C/T Associated with BMI Z-score in Singaporeans [78] 
    No effect on lifestyle intervention in overweight children and adolescents [79] 
 rs13278851  G/A No effect on lifestyle intervention in overweight children and adolescents [79] 
 rs17150703  G/A No effect on lifestyle intervention in overweight children and adolescents [79] 
SOD2 rs4880 Ala16Val C/T Val variant associated with MnSOD arrest in the inner mitochondrial membrane and 
lower dismutase efficiency 
[80] 
    Val allele associated with higher obesity risk in elderly [81] 
    Val allele show higher levels of IL-1, IL-6, TNFα, IFNγ and lower levels of IL-10 [82] 
    Val allele carriers show lower DNA damage levels [83] 
p22phox rs9932581 -930A/G A/G GG carriers have higher p22phox expression and NADPH oxidase activity [84] 
    GG carriers have higher HOMA-IR and insulin but not higher obesity risk [85] 
p22phox rs4673 242C/T C/T T allele type 2 diabetic carriers have lower IMT and 8-OHdG values, non-diabetic 
carriers have lower HOMA-IR and insulin 
[86] 
    CC carriers protected against diabetes and obesity, with lower plasma glucose levels and 
WC in hypertensive patients 
[87] 
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p22phox rs7195830  C/T C allele associated with higher obesity risk in women [88] 
p22phox rs12709102  T/C T allele associated with higher obesity risk in women [88] 
PPARγ rs1801282 Pro12Ala C/G Ala allele decreases receptor mediated transcriptional activity and is associated with 
lower BMI and increased insulin sensitivity 
[89] 
    Ala allele associated with increased BMI (+0.065 kg/m2 per allele) [90] 
PGC1α rs8192678 Gly482Ser G/A Ser allele associated with HOMA-IR in obese subjects [91] 
    Ser variant associated with lower BMI, waist and hip circumference and total body fat in 
women 
[92] 
    Not associated with obesity or type 2 diabetes in overweight Chinese subjects but 
associated with high insulin, HOMA-IR and waist-hip ratio, as well as TBARS, in 
patients with hyperglycemia 
[93] 
    Ser male diabetic carriers have lower adiponectin plasma levels [94] 
    Ser carriers have higher HOMA-IR and insulin concentrations, but eight-week low 
calorie diet reduces the risk 
[95] 
* And their haplotype. Alleles: 1, major; 2, minor. A-FABP, adipocyte fatty acid-binding protein; BMI, body mass index; CAT, catalase; DBP, diastolic blood pressure; 
dbSNP, database of the National Center for Biotechnology Information for short genetic variations; GPX, glutathione peroxidase; HOMA-β, homeostasis model 
assessment of β-cell function; HOMA-IR, homeostasis model assessment of insulin resistance; IFN-γ, interferon gamma; IL, interleukin; IMT, intima media thickness; 
LDL, low density lipoprotein; MDA, malondialdehyde; NADPH, nicotinamide adenine dinucleotide phosphate-oxidase; p22phox, cytochrome b-245 alpha polypeptide; 
PON1, paraoxonase 1; PRDX3, peroxiredoxin 3; PGC1α, peroxisome proliferator-activated receptor γ coactivator-1α; PPARγ, peroxisome proliferator activated receptor 
gamma; SBP, systolic blood pressure; SOD2, manganese superoxide dismutase; TAG, triglycerides; TBARS, thiobarbituric acid reactive substances; TNFα, tumor 
necrosis factor alpha; WC, waist circumference; 8-OHdG, 8-hydroxy-2'-deoxyguanosine. 
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Its genetic variation has traditionally been studied for diseases other than obesity. Due to this fact, 
our group recently published a study conducted on obese children that showed the association of some 
SNPs located in the CAT promoter with obesity [15] (Figure 2, Table 2). We found that the presence 
of the rare SNP variants, rs769214 (-844A/G), rs7943316 (-89T/A) and rs1049982 (-20C/T), was 
significantly and positively associated with prepubertal obesity. All of these SNPs were in linkage 
disequilibrium (LD) and formed a haplotype that had been previously described as associated with 
lower CAT expression in human cell lines under high oxidative stress [66]. The association between 
these SNPs and the principal insulin resistance and obesity markers was also studied, and we found 
that SNP rs769214 is associated with significantly higher weight, body mass index (BMI) Z-score and 
adipocyte fatty acid-binding protein (A-FABP), as well as with a higher plasma insulin concentration 
(not significant), without any observed effect on erythrocyte CAT activity. Another variant 
investigated was the SNP rs1001179 (-262C/T) in the 5' untranslated region (UTR) of the CAT gene. 
Several studies demonstrated that the T allele was associated with lower CAT enzyme activity [96–98], 
whereas those results were rejected by others [99]. 
These results suggest that CAT activity and expression are involved in the defense mechanisms 
against obesity-derived metabolic complications. The presence of the described SNPs could lead to 
lower CAT transcriptional activity and, thus, to lower CAT expression levels and activity in the cell. 
This would further contribute to cellular oxidative stress and its effects on cell dysfunction by altering 
signaling cascades or increasing the damage to macromolecules by oxidation. 
4.3. Paraoxonases  
The PON family consists of three antioxidant isoenzymes. PON1 and PON3 are expressed mainly 
in the liver and kidneys and are found bound to high-density lipoproteins (HDL) in the circulation. 
They inhibit the lipid peroxidation of the LDL and HDL particles in plasma. PON2 is a more 
ubiquitous membrane-bound form, found in a variety of tissues. Regarding alterations in PON 
expression in obesity, only one study has been conducted, in pigs, where PON3 mRNA expression in 
fat tissue was positively correlated with subcutaneous, visceral and total body fat weight, indicating a 
potential role for PON3 in obesity [100]. 
In the case of PON1 activity in the context of obesity, some studies have found decreased 
paraoxonase and arylesterase activities in the obese [11,23,24], whereas others have not [25–27]. 
Similar findings have been observed in children, with some authors observing altered PON1  
activities [34–36], and others finding no PON1 activity changes in obesity in children [37]. 
PON1 activity is known to be influenced by environmental factors, such as age, diet or medications, 
but the main cause of variation is genetics [101]. Two missense SNPs in the PON1 gene, Q192R 
(rs662) and L55M (rs854560), have been traditionally studied (Figure 2, Table 2). Individuals with the 
192RR (ArgArg) genotype have higher paraoxon-degrading activity [67], while 55LL (LeuLeu) 
individuals exhibit increased serum PON1 concentrations [102]. A study conducted in Portuguese 
women showed an association of the R allele with a higher risk of obesity [26], whereas a study in 
Mexican adults revealed no association between the variant and risk of obesity [25]. Another study 
failed to find any association of the SNP with obesity in adolescents [68]. Our group recently 
published a study carried out in prepubertal children that also confirmed the lack of an effect of Q192R 
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on childhood obesity risk [37]. In this study, we described a novel PON1 SNP, rs854566, which was 
found to be associated with protection from obesity in children, perhaps due to an observed increase in 
PON1 lactonase activity, although PON1 activities did not show any differences between obese and 
normal-weight subjects (Figure 2). 
4.4. Peroxiredoxins  
PRDXs are a family of six thioredoxin-dependent peroxidases that degrade H2O2 in the cell. Recent 
studies have clearly shown that PRDXs contribute to ROS signaling, regulating cell proliferation, 
differentiation and apoptosis. PRDX3 is located exclusively in the mitochondria, where it scavenges up 
to 90% of the H2O2 produced in this organelle, followed by scavenging by GPX1 and GPX4 [103]. 
Taking into account that mitochondrial respiration is the principal ROS producer, PRDX3 is 
considered highly important in terms of antioxidant defenses and redox status regulation. 
PRDX3 levels have been observed to be decreased in the adipose tissue of obese mice and  
humans [44]. In the same study, PRDX3 knock-out mice exhibited increased fat mass, as well as 
increased adipogenic and lipogenic gene expression in adipose tissue, leading to an obese phenotype. 
Additionally, increased O2
•− levels and protein carbonylation were observed in mitochondria, together 
with defects in mitochondrial biogenesis. In addition, adiponectin was downregulated, and 
plasminogen activator inhibitor (PAI) was upregulated, in accordance with the presence of impaired 
glucose tolerance and insulin resistance observed in PRDX3 knock-down adipocytes. 
The impact of PRDX3 genetic variations on obesity has been investigated in only one nutrigenomic 
study, in which it was found that four SNPs in the PRDX3 gene and the haplotype they formed were 
associated with higher BMI and obesity in Japanese people, when combined with a high-fat diet  
(HFD) [69] (Figure 2, Table 2). The SNPs, rs3740562 (A/G), rs2271362 (C/T), rs7768 (G/C) and 
rs3377 (A/C), were significantly associated with BMI after a multiple testing Bonferroni correction, 
whereas rs1553850 (A/T) was not. The haplotypes, A-A-T-G-A and T-G-C-C-C, also showed a significant 
association with decreased and increased BMI, respectively. As an HFD induces ROS production, 
Hiroi et al. investigated its possible role in these associations. The study of the interactions between 
the genotypes and haplotypes and dietary fat intake revealed that these genetic associations could only 
be observed in the group with the high-fat intake. Moreover, the association of the genotypes with 
higher BMI was observed only in the high-fat intake group. Altogether, these findings indicated a role 
for PRDX3 genetic variations and fat intake in the modulation of BMI and obesity risk. 
More studies are needed to investigate the effects of these and other SNPs on enzyme levels and 
activities to elucidate the link between their presence and a higher risk of obesity. One hypothesis 
could be that, under a high-fat diet, PRDX3 could be saturated by the excessive ROS produced in the 
electron-transport chain. Further studies could help in defining the role of this haplotype, which 
perhaps decreases PRDX3 expression or activity, explaining the aforementioned findings. 
4.5. Superoxide Dismutases  
The three members of the SOD family are the first line of defense against ROS, eliminating the 
strong superoxide radical and producing H2O2 that can then be degraded by CAT, GPXs and  
PRDXs [104]. CuZn-SOD (SOD1) is a homodimer localized in the cytosol. Mn-SOD (SOD2) is a 
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tetramer localized in the mitochondria, and the extracellular tetramer CuZn-SOD (SOD3 or EC-SOD) 
is localized exclusively in extracellular spaces. MnSOD is one of the most important antioxidant 
enzymes, because most superoxide is produced in the mitochondria. 
EC-SOD levels have been observed to increase in the white and brown adipose tissue and in the 
plasma of obese mice. In the same study, TNFα and IL-1β levels were also observed to be higher in 
white adipose tissue, which could be interpreted as an adaptation by the adipose tissue to the enhanced 
oxidative stress associated with obesity [105]. However, in a study of type 2 diabetic patients,  
EC-SOD levels were shown to be reduced and inversely related to BMI and HOMA-IR [106]. 
Interestingly, overexpression of SOD1 or SOD2 in mice reduced oxidative stress in vivo [107] and 
protected mice against high-fat diet induced glucose intolerance and insulin resistance, but not against 
obesity [108,109]. In contrast, another study showed restricted growth for SOD1 knockout mice, 
indicating a malfunction in absorption, as seen by the accumulation of lipid droplets in enterocytes [110]. 
The best-known SOD2 SNP is rs4880 (C/T). It is located in the second exon, and its presence 
generates a change in the 16th amino acid in the mitochondrial targeting sequence of the protein from 
alanine to valine [111] (Figure 2, Table 2). The Val-MnSOD variant has been associated with the arrest 
of MnSOD in the inner membrane and lower MnSOD homotetramer formation in the mitochondrial 
matrix, together with a lower efficiency of the enzyme in dismutating O2
•− into H2O2 [80]. Strikingly, 
both alleles in their homozygous form have been found to be associated with an increased risk for a 
variety of diseases, perhaps due to the increased O2
•− or H2O2 levels in ValVal and AlaAla subjects, 
respectively. However, only the Val allele was found to be associated with a higher risk of obesity in 
the elderly [81]. In addition, the presence of the ValVal genotype was related to higher levels of  
pro-inflammatory cytokines, such as IL-1, IL-6, TNF-α and interferon gamma (IFN-γ), and lower 
levels of IL-10 [82]. In contrast, Val allele carriers from a healthy cohort showed lower baseline levels 
of DNA damage [83]. Another study found that the ValVal genotype was more frequent among obese 
children with non-alcoholic steatohepatitis than those without the disease, although this difference was 
not significant [112].  
These findings indicate that the role of superoxide in the origin of obesity-derived alterations should 
be investigated. Moreover, these data support MnSOD as an essential enzyme in the regulation of 
ROS, the levels of which need to be perfectly balanced so that metabolic complications are avoided. 
4.6. MsrA  
The methionine sulphoxide reductase A (MsrA) is a 26 kDa protein localized in the cytosol and 
mitochondria involved in the antioxidant defense repairing of oxidized proteins, specifically by 
reducing the methionine-S-sulphoxide epimers back to methionine, using thioredoxin as a cofactor. 
Protein oxidation is a reversible process that has been proposed as one of the mechanisms by which 
oxidative stress leads to metabolic alterations, such as insulin resistance [113,114]. Due to this fact, the 
alteration of protein repairing enzymes, such as MsrA, is thought to be a key potential disruptor of 
oxidized protein-based signaling regulation. In a study conducted in wild-type and high-fat diet-fed 
rats, Uthus and Picklo observed a reduction in MsrA activity of 25% in visceral adipose tissue in a 
tissue-specific manner [115]. Additionally, more recently, Styskal et al. showed that high-fat diet-fed 
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MSRA–/– mice develop a more severe insulin-resistant phenotype with parallel reduced insulin 
signaling compared to wild-type mice [42]. 
Moreover, several loci in the MSRA gene have been associated with visceral obesity  
(Figure 2, Table 2). The first SNP to be associated with obesity was rs7826222 (also named rs545854), 
found to be positively associated with waist circumference (WC) in a genome-wide association study 
(GWAS) meta-analysis conducted in adult Europeans [70]. This finding was confirmed in other studies 
in Caucasians [71] and Hispanic women [72]. Yeung et al. also found the minor allele C to be 
associated with an increase in type 2 diabetes risk in men [73]. However, other studies did not observe 
a significant association between the variant rs7826222 with BMI in Chinese women [74] or with 
metabolic syndrome [75] or visceral fat [76] in Japanese. Other described MSRA SNPs are  
rs473034 and rs516175, associated with extreme childhood obesity [77] and the BMI Z-score in 
Singaporeans [78], respectively. In another study, Scherag et al. found no effect of three genetic 
variants near the MSRA gene (rs13278851, rs17150703 or rs516175 on a one-year lifestyle 
intervention to reduce weight in overweight children and adolescents [79]. Further studies 
investigating the potential role of these genetic variants in MsrA activity or expression are needed. 
5. The ROS Producer: NADPH Oxidase  
One of the most important ROS producers in cells is the NADPH oxidase complex, which generates 
O2
•− and, subsequently, other ROS, such as H2O2, during the phagocyte respiratory burst [116]. 
However, its activity is not limited to phagocytes, as other cells use NADPH oxidase-generated ROS 
as signaling mechanisms. It is known that insulin and cytokines act on this enzymatic complex, 
stimulating H2O2 production and providing a link between ligand binding and the intracellular redox 
state contributing to intracellular signaling cascades [39]. This complex is formed from six subunits, 
p22phox and gp91phox, which form cytochrome b558, p47phox, p67phox, p40phox, and rac. This 
enzymatic complex generates free radicals from oxygen and NADPH. 
The SNP -930A/G in the promoter of the p22phox gene was found to be associated with higher 
p22phox expression and NADPH oxidase activity in phagocytic cells from hypertensive patients 
carrying the GG genotype [84] (Figure 2, Table 2). The higher NADPH oxidase activity resulted in 
higher ROS production, which, in turn, increased the risk of insulin resistance [117]. Along these lines, 
the GG genotype was associated with higher HOMA-IR and insulin, but not with obesity, in a cohort 
of obese and normal weight Spanish subjects [85]. Another SNP in the p22phox subunit is 242C/T 
(Figure 2). Japanese type 2 diabetic patients carrying the T allele of this SNP showed a significantly 
lower intima media thickness (IMT) and lower 8-hydroxy-2'-deoxyguanosine (8-OHdG) values  
(not significant), whereas the non-diabetic T allele carriers were protected against insulin resistance, 
exhibiting lower HOMA-IR and fasting plasma insulin values [86]. However, another study reported 
that the CC genotype conferred protection against diabetes mellitus and obesity and was associated 
with lower fasting plasma glucose levels and waist circumference in hypertensive patients [87]. Other 
studied SNPs include rs7195830 (C allele) and rs12709102 (T allele), which were associated with a 
higher risk of obesity in women [88]. 
All of these findings taken together indicate that higher NADPH oxidase activity, and the 
concomitant ROS production could act in modulating the insulin signaling pathway. The genetic 
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variations in the genes of NADPH oxidase subunits should be further investigated to better understand 
their impact on enzymatic activity and the consequences on insulin signaling. This phenomenon could 
be a link between obesity and insulin resistance. Knowing the genotype of obese patients could help in 
treating them against further damaging metabolic complications. 
6. ROS Response Mechanisms: Transcription Factors  
6.1. PPARγ  
The nuclear hormone transcription factor, PPARγ, regulates adipogenic differentiation and lipid 
metabolism. Its expression is increased in the adipose tissue of obese individuals [118,119]. It binds to 
lipophilic ligands, such as poly-unsaturated fatty acids, prostaglandin derivatives and oxidized fatty 
acids [120]. Some studies have shown that PPARγ plays a role in the regulation of the antioxidant 
response to ROS, although the results are divergent. In a study in mice, it was shown that the adipose 
tissue-specific loss of an allele of PPARγ, with the subsequent loss of activity, was associated with 
more resistance to paraquat-induced oxidative stress. This was at least partially mediated through the 
upregulation of ROS scavenging genes, including GPX1, glutathione reductase, PRDX3, SOD2 and 
CAT, and the upregulation of the ROS responding transcription factor FOXO3A in adipose tissue [45]. 
This study concluded that reduced PPARγ activity in adipose tissue has beneficial effects. However, in 
another study, the authors showed that the activation of PPARγ by its ligands decreased TNFα or 
glucocorticoid-induced ROS production in human adipocytes [41]. In a previous study, Itoh et al. 
hypothesized that oxidative stress could exert some of its effects on intracellular signaling through 
PPARγ, and indeed, they showed that PPARγ expression was downregulated by H2O2, TNFα and 
lysophosphatidyl choline, which is the major constituent of oxidized LDL [46]. 
The best-known SNP in the PPARγ gene is rs1801282, which generates an amino acid change in the 
protein at codon 12 from proline to alanine (Pro12Ala) (Figure 2, Table 2). The effect of this SNP has 
been investigated in many previous studies with inconsistent results. The presence of the Ala allele 
was shown to decrease receptor-mediated transcription activity and to be associated with a lower BMI 
and increased insulin sensitivity [89]. However, in a recent meta-analysis that included almost  
50,000 subjects, the authors showed that individuals carrying the Ala allele have an increased BMI 
(+0.065 kg/m2), with a stronger effect in Caucasians [90].  
Although it seems that PPARγ has a role in ROS clearance from adipose tissue, its paradoxical 
function has yet to be investigated, to clarify whether the activation of PPARγ decreases ROS 
production or increases ROS scavenging. Moreover, the association of the Ala allele with obesity 
needs to be clarified in a controlled experimental setting while carefully studying ROS production. 
6.2. PGC1α  
PGC1α is a transcriptional co-activator of PPAR α and γ and controls mitochondrial biogenesis, 
adaptive thermogenesis, oxidative metabolism and glucose homeostasis. In these ways, it increases the 
oxidative metabolism that will lead to oxidative stress. However, PGC1α also induces the expression 
of ROS detoxifying enzymes, thus allowing for enhanced oxidative metabolism while controlling the 
associated ROS production [47,48]. 
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The PGC1α locus harbors the SNP, rs8192678, which results in an amino acid substitution of 
glycine to serine at position 482 (Gly482Ser) (Figure 2, Table 2). Fanelli et al. found that the 
Gly482Ser variant was associated with HOMA-IR in obese non-diabetic subjects [91]. In another 
study, the Gly482Ser variant was significantly associated with a lower BMI, waist and hip 
circumference and total body fat, but only in women [92]. This SNP was not found to be associated 
with obesity or type 2 diabetes in overweight non-diabetic Chinese individuals, but it was associated 
with high insulin, HOMA-IR and waist-hip ratios, as well as with TBARS in hyperglycemia [93]. 
Because adiponectin is under the transcriptional control of PPARγ, a target of PGC1α, Okauchi et al. 
studied the effects of the Gly482Ser variant on adiponectin plasma levels and found lower adiponectin 
concentrations in type 2 diabetic men, but not in women, carrying the polymorphism [94]. In this 
study, they ruled out the possibility that this variant is a functional polymorphism, and they suggested 
that the causative SNP could be in linkage disequilibrium (LD) with the common Gly482Ser variant. 
Along these lines, a previous functional study had already determined that neither the Gly482Ser nor 
Trp612Met variants of PGC1α affected the functionality of the protein regarding its co-activator 
activity on PPARγ2 [121]. A study conducted on the Gly482Ser polymorphism showed a basal 
association for the Ser-Ser genotype with higher HOMA-IR and insulin concentrations, but an 
intervention with an eight-week low-calorie diet reduced the risk level to that of non-carriers [95]. 
These results indicate that the Gly482Ser variant has an effect on obesity-associated comorbidities, 
such as insulin resistance, although it is most likely another SNP that is responsible for these effects. 
6.3. NRF2  
The transcription factor NRF2 regulates cellular responses to oxidative stress and other endogenous 
and exogenous stresses. Its role in obesity, type 2 diabetes and metabolic syndrome has already been 
investigated in many studies using animal models, as reviewed in [122]. NRF2 is regulated mainly 
through its binding to Kelch-like ECH-associated protein 1 (KEAP1) in the cytoplasm, which leads to 
its proteasomal degradation. The NRF2/KEAP1 pathway responds to oxidative stress via the control of 
several antioxidant defense gene expressions harboring the antioxidant response element (ARE) 
sequence in their promoter (Figure 2). 
Along with its role in the response against oxidative stress, NRF2 also modulates adiposity and 
adipogenesis. In fact, protein levels of NADPH quinone oxidoreductase (NQO1), which is under the 
transcriptional control of NRF2, increase during the initial stages of the adipogenic differentiation 
process (days 1–3). Moreover, in addition to NQO1, NRF2 and KEAP1 mRNA levels are also 
increased in differentiated adipocytes (days 11–14) [123]. This finding has been further confirmed by 
Hou et al., who found that the lack of NRF2 in 3T3-L1 cells blocked adipogenic differentiation by 
suppressing CCAAT/enhancer-binding protein beta (CEBPβ) expression, which is needed to trigger 
the differentiation process [124]. In contrast, Chartoumpekis et al. observed lower NRF2 abundance in 
the nucleus during adipogenesis, which they hypothesized could lead to the higher ROS levels needed 
for the differentiation process [125]. 
Among the in vivo studies on the role of NRF2 in obesity, the main conclusion from knock-out 
studies in mice is that the targeted disruption of NRF2 decreases adipose tissue mass and protects mice 
from long-term HFD-induced obesity [126,127]. NRF2 knock-out mice are partially protected from 
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HFD-induced obesity and insulin resistance. This effect may be due to the effect of fibroblast growth 
factor 21 (FGF21); the mRNA levels of FGF21 in the liver and white adipose tissue were elevated in 
NRF2 knock-out mice. The opposite effect, i.e., lower FGF21 mRNA levels, was observed  
when NRF2 was overexpressed [126]. In another study, Shin et al. observed the same effects of the 
NRF2 knock-out. However, they also tested the pharmacological activation of NRF2 by  
2-cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) and observed that it also protected 
from obesity by facilitating higher energy expenditure [128]. One of the main questions arising from 
these findings concerns which tissue is responsible for the NRF2 effect. One experiment with myeloid 
cells showed that deficiency in this tissue did not protect mice from HFD-induced adipose tissue 
inflammation and insulin resistance [129]. As Chartoumpekis et al. state in their review, Cre-loxP 
system experiments with tissue-specific knock-out models would help further clarify this issue. To our 
knowledge, only one study of NRF2 in humans has been published, demonstrating how the NRF2 
pathway was enriched in individuals with high-fat percentages [130]. 
Many SNPs have been described for the NRF2 gene in both mice and humans, although the 
association of NRF2 SNPs and obesity has not been studied. However, other diseases, such as 
pulmonary disease, breast cancer and gastrointestinal and autoimmune disorders, have shown different 
associations with NRF2 SNPs [131]. The SNP at position −178C/A conferred lower promoter activity 
in carriers of the A allele [132]. Interestingly, all evidence indicates that promoter and intronic SNPs 
are the ones that most show associations with the conditions studied, with no exonic SNP described so far. 
7. Conclusions  
The study of genetic variants in antioxidant defense genes, as well as in the genes of enzymes 
involved in the generation of ROS, could assist in better understanding the role of antioxidant defenses 
in protecting against obesity and its derived metabolic complications. There are data supporting the 
fact that obesity occurs along with enhanced ROS production, either due to misbalanced ROS 
scavenging systems or to enhanced oxidative stress production in cells. These effects can be due to 
excessive caloric intake and the saturation of the electron transport chain, as well as to free radical 
generation from cellular systems, such as the NADPH oxidase complex, in response to the altered 
insulin or cytokine production that is characteristic of obesity. However, it is becoming clear that ROS 
themselves can act by increasing adipogenesis and, thus, helping in the development of obesity. 
Although the reality is most probably a mixture of these phenomena, further studies should be carried 
out to define the role of ROS in the early stages of the development of obesity and its metabolic 
alterations, such as insulin resistance. 
This review summarizes the studies that have been carried out to unravel the role of genetic variants 
in antioxidant defense enzymes and other important oxidative metabolism mediators in increasing the 
risk of obesity or its close comorbidities, such as insulin resistance. It must be stated that many of the 
association studies reviewed here need validation in independent candidate gene studies or GWAS. 
In addition, more studies investigating genetic variations in antioxidant defense system genes are 
needed to clarify the associations reviewed here, as well as more functional studies concerning these 
SNPs and their possible impact on enzyme expression levels and activities. 
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